{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:56:09Z","timestamp":1761058569644},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.clinthera.2006.10.023","type":"journal-article","created":{"date-parts":[[2006,12,6]],"date-time":"2006-12-06T12:11:17Z","timestamp":1165407077000},"page":"1658-1669","source":"Crossref","is-referenced-by-count":18,"title":["Onset of action of fexofenadine hydrochloride 60 mg\/ pseudoephedrine hydrochloride 120 mg in subjects aged \u2a7e 12 years with moderate to severe seasonal allergic Rhinitis: A pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies"],"prefix":"10.1016","volume":"28","author":[{"given":"Robert B.","family":"Berkowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"McCafferty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Bazelmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penny","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Meeves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuning","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Georges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2006.10.023_bib1","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1067\/mai.2001.118891","article-title":"Allergic rhinitis and its impact on asthma","volume":"108","author":"Bousquet","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2006.10.023_bib2","first-page":"147","article-title":"Rhinitis: A dose of epidemiological reality","volume":"24","author":"Settipane","year":"2003"},{"key":"10.1016\/j.clinthera.2006.10.023_bib3","first-page":"1225","article-title":"Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC","volume":"3517","author":"The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.10.023_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1398-9995.2000.00526.x","article-title":"Consensus statement on the treatment of allergic rhinitis","volume":"55","author":"van Cauwenberge","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2006.10.023_bib5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1365-2222.2000.00914.x","article-title":"Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis","volume":"30","author":"van Cauwenberge","year":"2000","journal-title":"Clin Fxp Allergy"},{"key":"10.1016\/j.clinthera.2006.10.023_bib6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0091-6749(99)70070-9","article-title":"Double-blind, placebocontrolled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once-daily) and cetirizine in seasonal allergic rhinitis","volume":"104","author":"Howarth","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2006.10.023_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.0022-0477.2001.01252.x","article-title":"A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis","volume":"32","author":"Wilson","year":"2002","journal-title":"Clin Fxp Allergy"},{"key":"10.1016\/j.clinthera.2006.10.023_bib8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1081-1206(10)62086-8","article-title":"Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion","volume":"89","author":"Berger","year":"2002","journal-title":"Ann Allerg Asthma Immunol"},{"key":"10.1016\/j.clinthera.2006.10.023_bib9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1398-9995.1998.tb03990.x","article-title":"Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion","volume":"53","author":"Horak","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2006.10.023_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0091-6749(99)70120-X","article-title":"The efficacy and safety of fexofenadine HCI and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis","volume":"104","author":"Sussman","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2006.10.023_bib11","first-page":"325","article-title":"Efficacy of once-daily desloratadine\/pseudoephedrine for relief of nasal congestion","volume":"23","author":"Schenkel","year":"2002"},{"key":"10.1016\/j.clinthera.2006.10.023_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00045391-199807000-00007","article-title":"Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis","volume":"5","author":"Kaiser","year":"1998","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2006.10.023_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1081-1206(10)61909-6","article-title":"Onset of action, efficacy, and safety of fexofenadine 60 mg\/ pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit","volume":"89","author":"Berkowitz","year":"2002","journal-title":"Ann Allergy Asthma lmmunol"},{"key":"10.1016\/j.clinthera.2006.10.023_bib14","first-page":"335","article-title":"Fexofenadine HCI 60 mg\/pseudoephedrine HCI 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhini tis symptoms, as assessed in an allergen exposure unit","volume":"25","author":"Berkowitz","year":"2004"},{"key":"10.1016\/j.clinthera.2006.10.023_bib15","first-page":"1077","article-title":"Efficacy and tolerability of astemizole-D and loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber","volume":"46","author":"Horak","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2006.10.023_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1081-1206(10)62280-6","article-title":"Onset-ofaction for antihistamine and decongestant combinations during an outdoor challenge","volume":"84","author":"Georgitis","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2006.10.023_bib17","article-title":"Allergic rhinitis: Clinical development programs for drug products","author":"US Food and Drug Administration","year":"2005","journal-title":"Draft guidance"},{"key":"10.1016\/j.clinthera.2006.10.023_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1081-1206(10)63062-1","article-title":"Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit","volume":"79","author":"Day","year":"1997","journal-title":"Ann Allergy Asthma lmmunol"},{"key":"10.1016\/j.clinthera.2006.10.023_bib19","first-page":"211","article-title":"Singlecenter, double-blind, randomized, parallel study comparing onset of action, efficacy, and safety of a single dose of fexofenadine HCI (Allegra) 180 mg compared with placebo in treating seasonal allergic rhinitis patients in an allergen exposure unit","volume":"24","author":"Berkowitz","year":"2003"},{"key":"10.1016\/j.clinthera.2006.10.023_bib20","first-page":"59","article-title":"Randomized doubleblind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: Duration of effect in subjects with seasonal allergic rhinitis","volume":"25","author":"Day","year":"2004"},{"key":"10.1016\/j.clinthera.2006.10.023_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/030079906X80305","article-title":"Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: A pharmacodynamic study of onset of action and efficacy","volume":"22","author":"Horak","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2006.10.023_bib22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1185\/030079904125003700","article-title":"A direct comparison of the efficacy of antihistamines in SAR and PAR: Randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit-the Vienna Challenge Chamber (VCC)","volume":"20","author":"Stubner","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2006.10.023_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1368-5031.2004.0117.x","article-title":"Comparative clinical efficacy, onset and duration of action of levo cetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the environmental exposure unit (FFU)","volume":"58","author":"Day","year":"2004","journal-title":"Int J Clin Pract"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806002633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806002633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T01:24:27Z","timestamp":1547169867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806002633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0149291806002633"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.10.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}